It is well-established that NAbs emerge in most patients within a few months following HIV infection and that the NAbs developed by individual patients primarily target the autologous virus. However HIV+ sera can also neutralize heterologous isolates (cross-neutralizing antibody responses). The epitope-specificity of these cross-neutralizing antibody responses is largely unknown. We examined HIV+ antiretroviral-naive patients and identified a small number of subjects that developed broad anti-HIV plasma cross-neutralizing antibody responses. The plasma of one patient neutralizes all isolated tested against, irrespective of clade. Epitope- mapping analysis indicated that the exceptionally broad plasma neutralizing activity of that subject is exclusively due to anti-CD4-BS antibodies. However, because most patients, irrespective of the breadth of their plasma cross-neutralizing antibody responses, develop anti- CD4-BS antibodies, we hypothesize that the epitope(s) recognized by that patient's anti-CD4- BS antibodies differ from those recognized by the anti-CD4-BS antibodies of most HIV+- patients. We propose to isolate and characterize anti-CD4-BS MAbs from that patient and also to examine how the virus manages to escape their action. We have also identified another patient that developed 4E10-like and 2F5-like antibodies. We propose to map the precise epitope of these antibodies and examine the viral determinants of escape from those antibodies in that patient. In most cases, however, we were unable to map the epitope-specificities of broad plasma cross-neutralizing antibody responses to a particular epitope on Env. Our proposed studies aim at identifying the epitopes recognized by broadly cross-reactive NAbs developed during natural HIV-infection. This analysis will provide insights into the pathways that lead to the development of cross-reactive NAbs during HIV-infection, their epitopes, and the determinants of viral-escape from broadly-cross-reactive NAbs. Information from such studies can be used to develop more effective immunogens.

Public Health Relevance

Our proposed studies aim at improving our understanding of the interaction between HIV and the immune system; specifically with B cell mediated neutralizing antibody responses. Such studies are significant since they will provide new information on the mechanisms of HIV- mediated pathogenesis that leads to AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI081625-06
Application #
8960102
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Lawrence, Diane M
Project Start
2010-01-01
Project End
2015-12-31
Budget Start
2014-10-01
Budget End
2015-12-31
Support Year
6
Fiscal Year
2014
Total Cost
$331,232
Indirect Cost
$138,365
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bonsignori, Mattia; Scott, Eric; Wiehe, Kevin et al. (2018) Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity 49:1162-1174.e8
Dosenovic, Pia; Kara, Ervin E; Pettersson, Anna-Klara et al. (2018) Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc Natl Acad Sci U S A 115:4743-4748
LaBranche, Celia C; McGuire, Andrew T; Gray, Matthew D et al. (2018) HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog 14:e1007431
Borst, Andrew J; Weidle, Connor E; Gray, Matthew D et al. (2018) Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. Elife 7:
Stamatatos, Leonidas; Pancera, Marie; McGuire, Andrew T (2017) Germline-targeting immunogens. Immunol Rev 275:203-216
Briney, Bryan; Sok, Devin; Jardine, Joseph G et al. (2016) Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166:1459-1470.e11
Yacoob, Christina; Pancera, Marie; Vigdorovich, Vladimir et al. (2016) Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Rep 17:1560-1570
Pritchard, Laura K; Spencer, Daniel I R; Royle, Louise et al. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6:7479
Jardine, Joseph G; Ota, Takayuki; Sok, Devin et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61
Cohen, Kristen W; Dugast, Anne-Sophie; Alter, Galit et al. (2015) HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN. J Immunol 194:2769-75

Showing the most recent 10 out of 19 publications